Anemia and the role of erythropoietin in diabetes

Journal of Diabetes and its Complications

Volumn 20, Issue 4, 2006, Pages 262-272

  McGill, Janet B ^a,b   Bell, David S H ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Anemia; Diabetes; Diabetic complications; Erythropoietin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE DERIVATIVE; ERYTHROPOIETIN; HEMOGLOBIN A1C; IRON; METFORMIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PENTOXIFYLLINE; PIOGLITAZONE; RECOMBINANT ERYTHROPOIETIN; ROSIGLITAZONE; SULFONYLUREA;

ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; AUTONOMIC NEUROPATHY; CARDIOVASCULAR DISEASE; CELL DAMAGE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; EXERCISE TOLERANCE; FATIGUE; FIBROBLAST; GLOMERULUS FILTRATION; HEART FAILURE; HEMOGLOBINOPATHY; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY TUBULE CELL; MICROANGIOPATHY; MORBIDITY; MORTALITY; NEUROPATHY; NONHUMAN; NUTRITIONAL DEFICIENCY; NUTRITIONAL STATUS; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEFICIENCY; QUALITY OF LIFE; RETINOPATHY; RISK ASSESSMENT; THROMBOSIS; VASCULAR DISEASE;

ANEMIA; DIABETES COMPLICATIONS; DIABETES MELLITUS; DISEASE PROGRESSION; ERYTHROPOIETIN; HUMANS;

EID: 33747013809     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2005.08.001     Document Type: Article

References (106)

1. Adams P.F., Hendershot G.E., Marano M.A., and For the National Center for Health Statistics. Current estimates from the National Health Interview Survey. Vital and Health Statistics 10 (1999) 1-2
2. Aehi-Oschner C.H., and Gray V.L. Fructosamine measurements in the adult with type 1 diabetes. Diabetes Care 18 (1999) 1619-1620
3. 1c caused by use of dapsone. Endocrine Practice 8 5 (2002) 370-372
4. Aston B.C., Muntner P., Levin A., Eustace J.A., and Coresh J. Association of kidney function with anaemia: The Third National Health and Nutrition Examination Survey (1988-1994). Archives of Internal Medicine 162 (2002) 1401-1408
5. Avinoah E., Ovnat A., and Charuzi I. Nutritional status seven years after Roux-en-Y bypass surgery. Surgery 111 (1992) 137-142
6. Banks S. Chronic pancreatitis: Clinical features and medical management. American Journal of Gastroenterology 81 (1986) 153-167
7. 12 malabsorption induced by metformin. Diabetes Care 23 9 (2000) 1227-1231
8. Baynes K.R., McIntosh C., and Feher M.D. Artifactually low glycated hemoglobin is a potential pitfall in diabetes management: Consider congenital hemolytic anemias. Practical Diabetes International 18 (2001) 103-106
9. Becerra S.P., and Amaral J. Erythropoietin-an endogenous retinal survival factor. New England Journal of Medicine 347 24 (2002) 1968-1970
10. Bell D.S.H. Heart failure: The frequent, forgotten and often fatal complication of diabetes. Diabetes Care 26 (2003) 2433-2441
11. Bell D.S.H. A comparison of agents used to manage type 2 diabetes. Need for reappraisal of traditional approaches. Treatments in Endocrinology 3 2 (2004) 67-76
12. Besarab A., Bolton W.K., Browne J.K., Egrie J.C., Nissenson A.R., Okamoto D.M., Schwab S.J., and Goodkin D.A. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New England Journal of Medicine 339 (1998) 584-590
13. Bianchi R., Bayukakilli B., Brines M., et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proceedings of the National Academy of Sciences of the United States of America 101 (2004) 823-828
14. Bohle A., Wehrmann M., Bogenschatz O., et al. The pathogenesis of chronic renal failure in diabetic nephropathy. Pathology, Research and Practice 187 (1991) 251-259
15. Bosman D.R., Osborne C.R., Marsden J.J., MacDougall I.C., Gardner W.N., and Watkins P.J. Erythropoeitin response to hyperemia in patients with autonomic neuropathy and non-diabetic chronic renal failure. Diabetic Medicine 19 (2002) 65-69
16. Bosman D.R., Winkler A.S., Marsden J.T., et al. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 24 3 (2001) 495-499
17. Breyer J.A., Pain P., Evans J.K., McGill J., Hunsicker L., and Lewis E. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. Kidney International 50 (1996) 1651-1658
18. Brunning R.D., Jacob H.S., Brenckman W.D., Jimenez-Pasquau F., and Goetz F.C. Fragmentation haemolysis in patients with severe diabetic angiopathy. British Journal of Haematology 34 2 (1976) 283-289
19. Calvillo L., Latini R., Kajstura J., Leri A., Anversa P., Ghezzi P., Salio M., Cerami A., and Brines M. Recombinant human erythropoietin protects the myocardium from ischemia reperfusion injury and promotes beneficial remodeling. Proceedings of the National Academy of Sciences of the United States of America 100 8 (2003) 4802-4806
20. Carmargo J.L., and Gross J.L. Conditions associated with very low values of glycohaemoglobin measured by an HPLC method. Journal of Clinical Pathology 57 (2004) 346-349
21. Casadevall N., Nata F.J., Viron B., et al. Pure red cell aplasia due to anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. New England Journal of Medicine 346 (2002) 522-527
22. Ceriello A., Giugliano D., Quatraro A., et al. Vitamin E reduction of protein glycosylation in diabetes: New prospect for prevention of diabetic complications?. Diabetes Care 14 (1991) 68-72
23. Collins A. Annual data report: National Kidney Foundation Kidney Early Evaluation Program (KEEP). American Journal of Kidney Diseases 42 5 Suppl. 4 (2003) S52-S55
24. Collins A.J. Anemia management prior to dialysis: Cardiovascular and cost benefit observations. Nephrology, Dialysis, Transplantation 18 Suppl. 2 (2003) 2-6
25. Cooper A., Mikhail A., Lethbridge M.W., and Kemeny D.M. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. Journal of the American Society of Nephrology 15 (2004) 1877-1882
26. Cotroneo P., Maria Ricera B., Todaro L., et al. Blunted erythropoietin response to anemia in patients with type 1 diabetes. Diabetes/Metabolism Research and Reviews 16 3 (2000) 172-176
27. Craig K.J., Williams J.D., Riley S.G., Smith H., Owens D.R., Worthing D., Cavill I., and Phillips A.O. Anemia and diabetes in the absence of nephropathy. Diabetes Care 28 (2005) 1118-1123
28. Dallman P.R., Yip R., and Johnson C. Prevalence and causes of anemia in the United States, 1976 to 1980. American Journal of Clinical Nutrition 39 (1984) 437-445
29. David M.D., Fisher M.R., Gangnor R.E., et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science 39 2 (1998) 233-252
30. Davie S.J., Gould B.J., and Yudkin J.S. Effect of vitamin C on glycosylation of proteins. Diabetes 14 (1992) 68-72
31. DeBlock C., Van Gaal L., De Leeuw I., and The Belgian Diabetes Registry. High prevalence of manifestations of gastric autoimmunity in parietal cell-antibody positive type 1 (insulin-dependent) diabetic patients. Journal of Clinical Endocrinology and Metabolism 84 (1999) 4062-4067
32. De Block C.E.M., De Leeuw I.H., Van Gaal L.F., and The Belgian Diabetes Registry. High prevalence of manifestations of gastric autoimmunity in parietal cell antibody positive type 1 (insulin-dependent) diabetic patients. Journal of Clinical Endocrinology and Metabolism 84 (1999) 4062-4067
33. De Block C.E.M., Van Campenhout C.M., De Leeuw I.H., Keenoy B.M., Martin M., Van Hoof V., and Van Gaal L.F. Soluble transferring receptor level: A new marker of iron deficiency anemia, a common manifestation of gastric autoimmunity in type 1 diabetes. Diabetes Care 23 9 (2000) 1384-1388
34. De La Tour D.D., Raccah D., Jannot M.F., Coste T., Rongerie C., and Vague P. Erythrocyte Na/K ATPase activity and diabetes: Relationship with C-peptide level. Diabetologia 9 (1998) 1080-1084
35. Devendra D., and Eisenburth G.S. 17 Immunologic endocrine disorders. Journal of Allergy and Clinical Immunology 11 Suppl. 2 (2003) S624-S636
36. Dewar D.H., and Ciclitira P.J. Clinical features and diagnosis of celiac disease. Gastroenterology 128 (2005) S19-S24
37. 12 deficiency?. Quarterly Journal of Medicine 88 5 (1995) 357-364
38. Ehrenreich H., Hasselblatt M., Dembowski C., Cepek L., Lewczuk P., Stiefel M., Rustenbeck H.H., Breiter N., Jacob S., Knerlich F., Bohn M., Poser W., Rather E., Kochen M., Gefeller O., Gleiter C., Wessel T.C., DeRyck M., Itri L., Prane H., Cerami A., Brines M., and Siren A.L. Erythropoietin therapy for acute stroke is both safe and beneficial. Molecular Medicine 8 8 (2002) 495-505
39. Fenjues E.S., Ochoa M.S., Gaj-Robenstein C., et al. Adenoviral gene transfer of erythropoietin confers cytoprotection to isolated pancreatic islets. Transplantation 77 1 (2004) 13-18
40. Fine L.G., Bandyopadhay D., and Norman J.T. Is there a common mechanism for the progression of different types of renal disease other than proteinuria? Toward the unifying theme of chronic hypoxia. Kidney International 57 Suppl. 75 (2000) S22-S26
41. Fisher J.W. Erythropoietin: Physiology and pharmacology update. Experimental Biology and Medicine 228 (2003) 1-14
42. Foley R.N., Murray A.M., Li S., Herzog C.A., McBean A.M., Eggers P.W., and Collins A.J. Chronic kidney disease and the risk for cardiovascular disease, renal replacement and death in the United States Medicare Population, 1998 to 1999. Journal of the American Society of Nephrology 16 (2005) 489-495
43. Friedman E.A., Brown C.D., and Berman D.H. Erythropoietin in diabetic macular edema and renal insufficiency. American Journal of Kidney Diseases 26 (1995) 202-208
44. Fujioka K. Follow-up of nutritional and metabolic problems after bariatric surgery. Diabetes Care 28 (2005) 481-484
45. Gassman M., Heinicke K., Soliz J., et al. Non-erythroid functions of erythropoietin. Advances in Experimental Medicine and Biology 543 (2003) 323-330
46. Gimble J.M., Robinson C.E., Wu X., Kelly K.A., Rodriguez B.R., Kliewer S.A., Lehmann J.M., and Morris D.C. Peroxisome proliferator-activated receptor-activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Molecular Pharmacology 50 (1996) 1087
47. Gouva C., Nikolopoulos P., Ioannidis J.P.A., and Siamopoulos K.C. Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled clinical trial. Kidney International 66 (2004) 753-760
48. Grimm C., Wenzel A., Grosser M., et al. H1F-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nature Medicine 8 7 (2002) 718-724
49. Grune T., Sommerburg O., and Siems W.G. Oxidative stress in anemia. Clinical Nephrology 53 Suppl. 1 (2000) S18-S22
50. Hassan K., Simri W., Rubenchik I., Manelis J., Gross B., Shasha S.M., and Krist B. Effect of erythropoietin therapy on polyneuropathy in predialytic patients. Journal of Nephrology 16 1 (2003) 121-125
51. Henke M., Laszig R., Rube C., et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: A randomized, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
52. Hirase N., Yanase T., Mu Y., Muta K., Umemura T., Takayanagi R., and Nawata H. Thiazolidinedione suppresses the expression of erythroid phenotype in erythroleukemia cell line K562. Leukemia Research 24 (2000) 393-400
53. Hoeldtke R.D., and Streeten D. Treatment of orthostatic hypertension with erythropoietin. New England Journal of Medicine 329 (1993) 611-615
54. Holland D.C., and Lam M. Predictors of hospitalization and death among pre-dialysis patients: A retrospective cohort study. Nephrology Dialysis Transplantation 15 (2000) 650-658
55. Holland D.L., and Law M. Predictors of hospitalization and death among predialysis patients: A retrospective study cohort. Nephrology Dialysis Transplantation 15 5 (2000) 650-658
56. Jeffrey R.F., Kendall R.G., Prabhu P., Norfolk D.R., Will E.J., and Davidson A.N. Re-establishment of erythropoietin responsiveness in end-stage-renal failure following renal transplantation. Clinical Nephrology 44 4 (1995) 241-247
57. Juul S.E. Non-erythropoietic roles of erythropoietin in the fetus and neonate. Clinics in Perinatology 27 3 (2000) 527-541
58. Keane W.F., Brenner B.M., deZeeuw D., Grunfield P.J., McGill J., Mitch W.E., Ribiero A.B., Shahinfor S., Simpson R.L., Snappin S.M., Toto R., and RENAAL Study Investigators. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy. The RENAAL Study. Kidney International 63 (2003) 1499-1501
59. KEEP 2004 Data Report (2005). American Journal of Kidney Diseases 45 (3) (Suppl 2):S8-S13 and S76-S77.
60. King D.E., Mainous III A.G., Buchanan T.A., and Pearson W.S. C-Reactive protein and glycemic control in adults with diabetes. Diabetes Care 26 (2003) 1535-1539
61. Kuzminski A.M., DelGiacco E.J., Alen R.H., et al. Oral cobalamin therapy in patients who absorb it normally. Blood 92 12 (1998) 4879-4880
62. Lappin T. The cellular biology of erythropoietin receptors. Oncologist 8 Suppl. 1 (2003) 15-18
63. Lappin T.R., Maxwell A.P., Johnston P.G., et al. EPO's alter ego erythropoietin has multiple actions. Stem Cells 20 6 (2002) 485-492
64. Lavery L.A., Van Houtum W.H., and Armstrong D.G. Institutionalization following diabetes-related lower extremity amputation. American Journal of Medicine 103 5 (1997) 383-388
65. Leist M., Ghezzi P., Grasso G., et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305 5681 (2004) 239-242
66. Leyland-Jones B., and On behalf of the BEST Investigator and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncology 4 (2003) 459-460
67. Macdougall I.C., and Steering Committee of the CREATE trial; CREATE Study Group. CREATE: New strategies for early anaemia management in renal insufficiency. Nephrology Dialysis Transplantation 18 Suppl. 2 (2003) ii13-ii16
68. Marshall S.M., Home P.D., Manley S.E., et al. Standardization of glycosylated hemoglobin. Diabetic Medicine 19 (2002) 429
69. Masuda S., Okano M., Yamagishi K., et al. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. Journal of Biological Chemistry 269 30 (1994) 19488-19493
70. McClellan W.M., Flanders W.D., Langston R.B., Turkovitz C., and Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: A population-based study. Journal of the American Society of Nephrology 13 (2002) 1928-1936
71. Meloni G., and Meloni T. Glyburide induced acute hemolysis in a G6 PD-deficient patient with NIDDM. British Journal of Haematology 92 1 (1996) 159-160
72. Mix T.C.H., Brenner R.M., Cooper M.E., deZeeuw D., Ivanovich P., Levey A.S., McGill J.B., McMurray J.J.V., Parfrey P.S., Parving H.H., Pereira B.J.G., Remuzzi G., Singh A.K., Stehman-Breen C., Toto R., and Pfeffer M.A. Rationale-Trial to reduce cardiovascular events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal 149 (2005) 408-413
73. Mohanram A., Zhang Z., Shahinfar S., Keane W.F., Brenner B.M., and Toto R.D. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney International 66 (2004) 1131-1138
74. Moon C., Krawczyk M., Ahn D., Ahmet I., Park D., Lakatta E.G., and Talan M.I. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proceedings of the National Academy of Sciences of the United States of America 100 20 (2003) 11612-11617
75. 1c levels in patients with chronic renal failure on hemodialysis. Internal Medicine 37 (1998) 826-830
76. National Kidney Foundation: Kidney Disease Outcomes Quality Initiative. Clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Guideline 8. Association of level of GFR with anemia. American Journal of Kidney Diseases 39 2, Suppl. 1 (2002) S120-S127
77. Navarro J.F. In the erythropoietin era, can we forget alternative or adjunctive therapies for renal anaemia management? The androgen example. Nephrology, Dialysis, Transplantation 18 (2003) 222-226
78. Palmer B.F. Outcomes associated with hypogonadism in men with chronic kidney disease. Advances in Chemical Kinetics and Dynamics 11 (2004) 342-347
79. Parfrey P.S., Foley R.N., Harnett J.D., Kent G.M., Murray D.C., and Barre P.E. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrology, Dialysis, Transplantation 11 (1996) 1277-1285
80. Parsa C.J., Kim J., Riel R.U., Pascal C.S., Thompson R.B., Petrofski J.A., Matsumoto A., Stamler J.S., and Koch W.J. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: A potential role for cardiac fibroblasts. Journal of Biological Chemistry 279 20 (2004) 20655-20662
81. Perros P., Singh R.K., Ludlam C.A., et al. Prevalence of pernicious anemia in patients with type 1 diabetes mellitus and autoimmune thyroid disease. Diabetic Medicine 17 10 (2000) 749-751
82. Pinero-Pilona A., Litonjua P., Devaraj S., Aviles-Santa L., and Raskin P. Anemia associated with new-onset diabetes: Improvement with blood glucose control. Endocrine Practice 8 (2002) 276-278
83. Pyamali A., Becker T., Simmons W.P., Johnson C.A., Premasthian A., and Becker B.N. Increasing hematocrit reduces early post transplant cardiovascular risk in diabetic transplant recipients. Transplantation 76 5 (2003) 816-820
84. Quio Q., Keinanen-Kiukaanniemi S., and Laara E. The relationship between hemoglobin levels and diabetic retinopathy. Journal of Clinical Epidemiology 50 (1997) 153-158
85. Riley W.J., Toskes P.P., Maclaren N.K., and Silverstein J. Predictive value of gastric parietal cell autoantibodies as a marker for gastric and hematologic abnormalities associated with insulin-dependent diabetes. Diabetes 31 (1982) 1051-1055
86. Rizzo J.D., Seidenfeld J., Piper M., Aronson N., Lichtin A., and Littlewood T.J. Erythropoietin: A paradigm for the development of practice guidelines. Hematology (2001) 10-30
87. Rodriguez-Garcia J.L., and Fraile G. Iron deficiency in autoimmune chronic gastritis. Postgraduate Medicine Journal 66 (1990) 686-687
88. Ross S.D., Fahrbach K., Frame D., Scheye R., Connelly J.E., and Glaspy J. The effect of anemia treatment on selected health-related quality-of-life domains: A systematic review. Clinical Therapeutics 25 (2003) 1786-1805
89. Rossing K., Christensen P.K., Hovind P., Tarnow L., Rossing P., and Parving H.H. Progression of nephropathy in type 2 diabetic patients. Kidney International 66 (2004) 1-10
90. 1c). Diabetes/Metabolism Research and Reviews 17 (2001) 94-98
91. Sharma R., Francis D.P., Pitt B., Poole-Wilson P.A., Coats A.J., and Anker S.D. Hemoglobin predicts survival in patients with chronic heart failure: A substudy of the ELITE II trial. European Heart Journal 25 12 (2004) 1021-1028
92. Silverberg D.S., Wexler D., Blum M., and Tchebner J.Z. The effect of correction of anemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrology, Dialysis, Transplantation 18 1 (2003) 161-166
93. Singh N.P., Chandrashekhar N.M., Anuradha S., Kohli R., and Agarwal S.K. The cardiovascular and hemodynamic effects of erythropoietin in chronic renal failure. Journal of the Association of Physicians of India A48 3 (2000) 301-306
94. Skroubis G., Sakellaropoulos G., Pouggouras K., Mead N., Nikiforidis G., and Kalfarentzos F. Comparison of nutritional deficiencies after Roux-en-Y gastric bypass and after biliopancreatic diversion with Roux-en-Y gastric bypass. Obesity Surgery 12 4 (2002) 551-558
95. Spivak, J. L. (2001). Erythropoietin use and abuse: When physiology and pharmacology collide. In R. C. Roach, P. D. Wagner, & P. H. Hackett (Eds.), Hypoxia: From genes to the bedside (pp. 207-224). New York: Kluwer Academic Press/Plenum Publishers.
96. Strippoli G.F.M., Craig J.C., Manno C., and Schena F.P. Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. Journal of the American Society of Nephrology 15 (2004) 3154-3165
97. Szachniewicz J., Petruk-Kowalczy K.J., Majda J., Kaczmarck A., Reszuch K., Kalra K., Piepoli M.F., Anker S.D., Barasia K.W., and Ponikowski P. Anemia is an independent predictor of poor outcome in patients with chronic heart failure. International Journal of Cardiology 90 (2003) 303-308
98. Thomas D.R. Anemia and quality of life: unrecognized and undertreated. Journal of Gerontology 59A 3 (2004) 238-241
99. Thomas M.C., MacIsaac R.J., Tsalamandris C., Molyneaux L., Goubina I., Fulcher G., Yue D., and Jerums G. Anemia in patients with type 1 diabetes. Journal of Clinical Endocrinology and Metabolism 89 (2004) 4359-4363
100. Thomas M.C., MacIsaac R.J., Tsalamandris C., Power D., and Jerums G. Unrecognized anemia in patients with diabetes: a cross-sectional survey. Diabetes Care 26 (2003) 1164-1169
101. Ueda H., Yokoyama H., Ishimura E., Shojl T., Emoto M., Morioka T., Matsumota N., Fukumoto S., Miki T., Inaba M., and Nishizawa Y. Factors affecting progression of renal failure in patients with type 2 diabetes. Diabetes Care 26 5 (2003) 1530-1534
102. Weiss G., and Goodnough L.T. Anemia of chronic disease. New England Journal of Medicine 352 (2005) 1011-1023
103. Wellen K.E., and Hotamisligil G.S. Inflammation, stress and diabetes. Journal of Clinical Investigation 115 (2005) 1111-1119
104. Winkler A.S., Marsden J., Chaudhuri K.R., et al. Erythropoietin depletion and anemia in diabetes mellitus. Diabetic Medicine 16 10 (1999) 813-819
105. 12 in type 2 diabetes mellitus: a randomized placebo-controlled trial. Journal of Internal Medicine 255 2 (2004) 302-303
106. Yokoyama H., Tomonaga O., Hirayama M., Ishii A., Takeda M., Babazoro T., Ujihara U., Takashashi C., and Omori Y. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM. Diabetologia 40 (1999) 405-411